An observational study in Myocardial Infarction, MINOCA and Inflammation, sponsored by Hospital Universitario Getafe. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-06.
Sponsored by Hospital Universitario Getafe · Observational
Around 10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA) which pathophysiology is often uncertain. The aim of the study is to evaluate inflammation and endothelial dysfunction biomarkers in MINOCA patients during both acute and stable phases, comparing them with those with MI and obstructive coronary arteries (MICAD).
Prospective observational study in patients with Myocardial Infarction (MI) divided into two groups: MI with obstructive coronary arteries (MICAD) and MI with non-obstructive coronary arteries (MINOCA). Levels of interleukin-6, tumor necrosis factor-alpha, high-sensitivity C- reactive protein, and asymmetric dimethylarginine will be determined at three time points: within the 24 hours from the onset of pain, discharge, and two months after MI. The association of biomarkers, normalized by peak troponin value, with the risk of MINOCA will be evaluated using logistic regression.
29 studies on the registry are indexed under MINOCA; 18 are open to participants now.
This study's planned enrollment of 400 is below the median of 500 across 20 observational studies indexed under MINOCA.
Browse MINOCA studies →Hospital Universitario Getafe is the lead sponsor of 29 studies on the registry; 3 are open to participants now.
Compared within MINOCA, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients older than 18 years old admitted to our hospital with Myocardial Infarction and undergo a coronariography.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Myocardial Infarction and Obstructive Coronary Arteries
Diagnostic Test: Coronariography
Patients with Myocardial Infarction and Non-obstructive Coronary Arteries
Diagnostic Test: Coronariography
Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml)
Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml) will be determined.
Time frame: At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of endhotelial disfunction biomarkers
Levels of asymmetric dimethylarginine will be determined
Time frame: At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Levels of high-sensitivity C-reactive protein (mg/L)
Levels of high-sensitivity C-reactive protein (mg/L) will be determined.
Time frame: t three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI.
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in May 2024, 43 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Getafe